St. Jude Medical snatched up Nanostim for at least $123.5 million, giving it bragging rights as the owner of the only leadless cardiac pacemaker to hit the market so far.
Catalent has snapped up a Brazilian contract manufacturer, expanding its hold on the global softgel market by growing its presence in Latin America.
The private equity firm will reportedly pay about $150 million for nearly 30% of the drugmaker, which makes heparin and some other products for the cardiovascular and orthopedic segments.
C.R. Bard's $262 million cash bid for Rochester Medical is hitting the home stretch. The soon-to-be acquired company will hold a special shareholder meeting Nov. 13 to approve the deal. Rochester Medical shareholders aren't likely to put up much of a fuss.
With Johnson & Johnson's cancer treatment Doxil expected to run short till the end of 2014, India's Sun Pharmaceutical Industries stands to gain. To meet demand amid previous scarcity, the FDA allowed Sun's unapproved generic version of the drug to be imported into the U.S. Now, after a fast-track approval process, the drug has FDA's blessing, and Sun will have the market all to itself, at least for now.
The online chatter in Bloomberg and Reuters about potential Roche deals has been flying fast and furious recently, but there's been a streak of unfounded rumors that appear to be more smoke than fire.
News flash from Basel: Yes, Novartis really is considering selling off a few of its units, in deals that could be worth $15 billion to $20 billion. And no, Roche and Novartis aren't likely to embark on any big joint projects, much less consider a merger.
Quest Diagnostics is boosting its presence in the lucrative New England market with the acquisition of a regional laboratory testing services-company in Massachusetts--its fourth deal in the space so far this year and its second in the Bay State. Quest gains ConVerge Diagnostic Services, a Peabody, MA-based operation that had been owned by the investor Water Street Healthcare Partners.
While med tech M&A didn't exactly shoot for the moon in the first half of the year, the industry's dealmakers have been far more feverish ever since, inking billion-dollar buyouts and slamming shut months of speculation. Now, as New Year's approaches, some of the field's most sought-after targets are still up for grabs.
Biomet has signed a deal to acquire the venture-backed Lanx, looking to grab a bigger share of the spine market as demand for hip and knee implants wanes.